KR100926410B1 - 세티리진 및 슈도에페드린을 포함하는 정제 - Google Patents

세티리진 및 슈도에페드린을 포함하는 정제 Download PDF

Info

Publication number
KR100926410B1
KR100926410B1 KR1020037017054A KR20037017054A KR100926410B1 KR 100926410 B1 KR100926410 B1 KR 100926410B1 KR 1020037017054 A KR1020037017054 A KR 1020037017054A KR 20037017054 A KR20037017054 A KR 20037017054A KR 100926410 B1 KR100926410 B1 KR 100926410B1
Authority
KR
South Korea
Prior art keywords
tablet
cetirizine
pseudoephedrine
segment
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037017054A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007756A (ko
Inventor
도메니코 파나라
안토니 귀차욱스
모니크 베르와에르
미첼 델리어스
Original Assignee
유씨비 파쉼 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 파쉼 소시에떼아노님 filed Critical 유씨비 파쉼 소시에떼아노님
Publication of KR20040007756A publication Critical patent/KR20040007756A/ko
Application granted granted Critical
Publication of KR100926410B1 publication Critical patent/KR100926410B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020037017054A 2001-06-28 2002-06-10 세티리진 및 슈도에페드린을 포함하는 정제 Expired - Lifetime KR100926410B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30125001P 2001-06-28 2001-06-28
EP01115807 2001-06-28
EP01115807.8 2001-06-28
US60/301,250 2001-06-28
PCT/EP2002/006342 WO2003002098A1 (en) 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097004649A Division KR20090029314A (ko) 2001-06-28 2002-06-10 세티리진 및 슈도에페드린을 포함하는 정제

Publications (2)

Publication Number Publication Date
KR20040007756A KR20040007756A (ko) 2004-01-24
KR100926410B1 true KR100926410B1 (ko) 2009-11-12

Family

ID=56290291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037017054A Expired - Lifetime KR100926410B1 (ko) 2001-06-28 2002-06-10 세티리진 및 슈도에페드린을 포함하는 정제

Country Status (22)

Country Link
EP (1) EP1404304B1 (enExample)
JP (1) JP4041460B2 (enExample)
KR (1) KR100926410B1 (enExample)
CN (1) CN100490809C (enExample)
AT (1) ATE432068T1 (enExample)
AU (1) AU2002345024B2 (enExample)
BR (1) BR0210650A (enExample)
CA (1) CA2451519C (enExample)
CZ (1) CZ20033454A3 (enExample)
DK (1) DK1404304T3 (enExample)
EE (1) EE05357B1 (enExample)
ES (1) ES2324769T3 (enExample)
HU (1) HU229803B1 (enExample)
MX (1) MXPA03010430A (enExample)
NZ (1) NZ530289A (enExample)
PL (1) PL206069B1 (enExample)
PT (1) PT1404304E (enExample)
RO (1) RO122476B1 (enExample)
RU (1) RU2286784C2 (enExample)
SI (1) SI1404304T1 (enExample)
SK (1) SK287645B6 (enExample)
WO (1) WO2003002098A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090966A (ko) 2011-07-15 2018-08-14 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232445D1 (de) * 2001-06-28 2009-07-09 Ucb Farchim Sa Cetirizin und pseudoephedrin enthaltende tablette
KR100698400B1 (ko) 2004-04-14 2007-03-23 이은주 탈모증 및 전립선비대증 치료를 위한 약제학적 조성물
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
EP2626067A1 (en) * 2006-12-26 2013-08-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
EP2799071B1 (en) 2010-06-16 2018-10-17 Inflammatory Response Research, Inc. Levocetirizine and montelukast for the treatment of influenza and common cold
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
KR101372324B1 (ko) * 2012-02-09 2014-03-13 동국대학교 경주캠퍼스 산학협력단 알러지성 비염 치료를 위한 한방 치료제 및 슈도에페드린을 함유한 복합서방형의 약제학적 조성물
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
KR20150135339A (ko) 2013-03-13 2015-12-02 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2016140630A1 (en) 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
EP4099977A1 (en) * 2020-02-03 2022-12-14 Johnson & Johnson Consumer Inc. A single layer chewable tablet comprising cetirizine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090966A (ko) 2011-07-15 2018-08-14 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제

Also Published As

Publication number Publication date
WO2003002098A1 (en) 2003-01-09
PT1404304E (pt) 2009-06-26
HU229803B1 (en) 2014-07-28
RU2004101231A (ru) 2005-04-20
RO122476B1 (ro) 2009-07-30
CN1520285A (zh) 2004-08-11
BR0210650A (pt) 2004-10-05
DK1404304T3 (da) 2009-07-13
MXPA03010430A (es) 2004-12-06
HUP0400386A3 (en) 2006-02-28
SK15502003A3 (sk) 2004-05-04
SK287645B6 (sk) 2011-05-06
ES2324769T3 (es) 2009-08-14
HUP0400386A2 (hu) 2004-08-30
CA2451519A1 (en) 2003-01-09
EE05357B1 (et) 2010-12-15
CA2451519C (en) 2007-11-06
RU2286784C2 (ru) 2006-11-10
PL366800A1 (en) 2005-02-07
SI1404304T1 (sl) 2009-10-31
CZ20033454A3 (cs) 2004-08-18
EP1404304A1 (en) 2004-04-07
PL206069B1 (pl) 2010-06-30
KR20040007756A (ko) 2004-01-24
CN100490809C (zh) 2009-05-27
AU2002345024B2 (en) 2006-09-07
EE200400005A (et) 2004-02-16
NZ530289A (en) 2004-11-26
ATE432068T1 (de) 2009-06-15
EP1404304B1 (en) 2009-05-27
JP2004536829A (ja) 2004-12-09
JP4041460B2 (ja) 2008-01-30

Similar Documents

Publication Publication Date Title
KR100926410B1 (ko) 세티리진 및 슈도에페드린을 포함하는 정제
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
JP2007176958A (ja) セチリジン及びプソイドエフェドリンを含む錠剤
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
US8263124B2 (en) Anthistamine-decongestant pharmaceutical compositions
HK1064596B (en) Tablet comprising cetirizine and pseudoephedrine
TWI243061B (en) Tablet comprising cetirizine and pseudoephedrine
KR20090104785A (ko) 안정한 서방출형의 경구 투여용 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071221

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080623

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20081205

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080623

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20071221

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090305

PJ0201 Trial against decision of rejection

Patent event date: 20090305

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20081205

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20091007

Appeal identifier: 2009101001987

Request date: 20090305

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090305

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090305

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080825

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080221

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070130

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090416

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20091007

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20090407

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20091104

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20091104

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20121019

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20121019

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20131017

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20131017

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20141023

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20141023

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20151012

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20151012

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160929

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20181018

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20201015

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20211015

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20221210

Termination category: Expiration of duration